Use of acalabrutinib in patients with mantle cell lymphoma

References

• Cheah CY, Seymour JF, Wang ML. Mantle cell lymphoma. J Clin Oncol. 2016;34:1256–1269.
   PubMed Web of Science ®Google Scholar
• Hoster E, Klapper W, Hermine O, et al. Confirmation of the mantle-cell lymphoma international prognostic index in randomized trials of the European mantle-cell lymphoma network. J Clin Oncol. 2014;32:1338–1346.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Harrington B, O’Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:323–332.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Jones JA, Furman RR, et al. Acalabrutinib, a second generation Bruton tyrosine kinase (Btk) inhibitor, in previously untreated chronic lymphocytic leukemia (CLL). J Clin Oncol. 2016;34:(suppl; abstr 7521).
   Web of Science ®Google Scholar
• Slupsky JR. Does B cell receptor signaling in chronic lymphocytic leukaemia cells differ from that in other B cell types? Scientifica (Cairo). 2014;2014:208928.
   PubMedGoogle Scholar
• Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood. 2012;120:1175–1184.
   PubMed Web of Science ®Google Scholar
• Cinar M, Hamedani F, Mo Z, et al. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by ibrutinib induces apoptosis. Leuk Res. 2013;37:1271–1277.
   PubMed Web of Science ®Google Scholar
• Saba NS, Liu D, Herman SE, et al. Pathogenic role of B-cell receptor signaling and canonical NF-kappaB activation in mantle cell lymphoma. Blood. 2016;128:82–92.
   PubMed Web of Science ®Google Scholar
• Ponader S, Burger JA. Bruton’s tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. J Clin Oncol. 2014;32:1830–1839.
   PubMed Web of Science ®Google Scholar
• Smith CI. From identification of the BTK kinase to effective management of leukemia. Oncogene. 2017;36:2045–2053.
   PubMed Web of Science ®Google Scholar
• Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol. 2016;9:21.
   PubMed Web of Science ®Google Scholar
• Barf T, Covey T, Izumi R, et al. Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase (BTK) inhibitor with a differentiated selectivity and in vivo potency profile. J Pharmacol Exp Ther. 2017. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• AstraZeneca Pharmaceuticals LP. Calquence (acalabrutinib) prescribing information. cited date 2017 Nov 3. Available from: https://www.calquence.com
   Google Scholar
• Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma: a single-arm, multicenter, phase 2 trial. 2018;391:659–667.
   Google Scholar
• Byrd JC, Wierda WG, Schuh A, et al. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated results from the phase 1/2 ACE-CL-001 study. Blood. 2017;130:498(abstract).
   PubMedGoogle Scholar
• National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: chronic lymphocytic leukemia/small lymphocytic lymphoma. NCCN Evidence Blocks Version cited date 2018 Apr 10 5.2018. Available from: NCCN.org
   Google Scholar
• Pharmacyclics & Janssens Biotech. Imbruvica (ibrutinib) prescribing information. [Accessed 2017 Sep 11]. Available from: https://www.janssenmd.com/pdf/imbruvica/imbruvica_pi.pdf
   Google Scholar
• Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–516.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.
   PubMed Web of Science ®Google Scholar
• electronic Medicines Compendium (eMC). Imbruvica 140 mg hard capsules. [updated 2017 Aug.30;cited date 2017 Sep 11]. Available from: https://www.medicines.org.uk/emc/medicine/29383
   Google Scholar
• Wu J, Liu C, Tsui ST, et al. Second-generation inhibitors of Bruton tyrosine kinase. J Hematol Oncol. 2016;9:80.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213–223.
   PubMed Web of Science ®Google Scholar
• O’Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15:48–58.
   PubMed Web of Science ®Google Scholar
• O’Brien S, Jones JA, Coutre SE, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016;17:1409–1418.
   PubMed Web of Science ®Google Scholar
• Wiczer TE, Levine LB, Brumbaugh J, et al. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Adv. 2017;1:1739–1748.
   PubMed Web of Science ®Google Scholar
• Covey T, Gulrajani M, Cheung J, et al. Pharmacodynamic evaluation of acalabrutinib in relapsed/refractory and treatment-naive patients with chronic lymphocytic leukemia (CLL) in the phase 1/2 ACE-CL-001 study. Blood. 2017;130:1741(abstract).
   Web of Science ®Google Scholar
• De Jong J, Sukbuntherng J, Skee D, et al. The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia. Cancer Chemother Pharmacol. 2015;75:907–916.
   PubMed Web of Science ®Google Scholar
• Wang M, Rule S, Zinzani PL, et al. Efficacy and safety of acalabrutinib monotherapy in patients (pts) with relapsed/refractory mantle cell lymphoma (R/R MCL) in the phase 2 ACE-LY-004 study. Blood. 2017;130:155(abstract).
   Google Scholar
• Awan FT, Schuh A, Brown JR, et al. Acalabrutinib monotherapy in patients with ibrutinib intolerance: results from the phase 1/2 ACE-CL-001 clinical study. Blood. 2016;128:638(abstract).
   Web of Science ®Google Scholar
• Byrd JC, Owen R, O’Brien SM, et al. Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in hematologic malignancies. Blood. 2017;130:4326(abstract).
   PubMedGoogle Scholar
• Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425–2437.
   PubMed Web of Science ®Google Scholar
• Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126:739–745.
   PubMed Web of Science ®Google Scholar
• Brown JR, Moslehi J, Ob S, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017;102:1796–1805.
   PubMed Web of Science ®Google Scholar
• Ghez D, Calleja A, Protin C, et al. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 2018. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Campo E, Hermine O, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv62–iv71.
   PubMed Web of Science ®Google Scholar
• Trneny M, Lamy T, Walewski J, et al. Lenalidomide versus investigator’s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. Lancet Oncol. 2016;17:319–331.
   PubMed Web of Science ®Google Scholar
• Chiron D, Di Liberto M, Martin P, et al. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov. 2014;4:1022–1035.
   PubMed Web of Science ®Google Scholar
• Cheah CY, Chihara D, Romaguera JE, et al. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015;26:1175–1179.
   PubMed Web of Science ®Google Scholar
• Martin P, Maddocks K, Leonard JP, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127:1559–1563.
   PubMed Web of Science ®Google Scholar
• Bouabdallah K, Tabrizi R, Vigouroux S, et al. Successful bridge with Ibrutinib monotherapy to allogeneic stem cell transplant in relapsed mantle-cell lymphoma: P626. Bone Marrow Transplant. 2017;52:S454 (abstract).
   Google Scholar
• Grillo G, Zucchetti E, Zilioli VR, et al. Ibrutinib as bridge therapy to allogeneic stem cell transplantation in refractory mantle cell lymphoma (MCL): a case report: P106. Bone Marrow Transplant. 2017;52:S169 (abstract).
   Google Scholar